Views & Analysis NICE plans to charge for appraisals – but pharma wants refor... Will NICE introduce fees for pharma companies' TAs from next year?
Views & Analysis PPRS and devolution: over £60m to Greater Manchester? Does the local NHS in England get its fair share of PPRS money?
Views & Analysis Meeting the challenges of rare disease treatment adherence HCPs, pharma and patients can pool their experience to develop effective, tailored support.
Views & Analysis Fighting diminishing HCP access Predictive sales analytics can help pharma reps make limited time with healthcare professionals count.
Views & Analysis Saving the jewel in the crown of ‘UKplc’: Brexit's impact on... Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
Partner Content Partner Content The new CDF - Navigating Cancer Drug Access in England On July 29th 2016, the new process in England for cancer drugs seeking license went live - changing both the shape and potential requirements of the submissions process.
News FDA orders blindness risk warning to GLP-1 agonist labels FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to their product labels for a rare eye condition that can cause blindness.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
